Fetal Thymus Involution as a Predictor of Adverse Neonatal Outcomes
Completed
Conditions studied: Women Admitted to Labor and Delivery for the Management of Preterm Labor and/or Preterm Premature Rupture of Membranes (PPROM)
In brief
The thymus gland is a specialized organ in the chest that plays a central role in the adaptive immune system throughout development until puberty. In response to stress, the fetal thymus gland may shrink, or involute. The investigators propose a prospective cohort study that will enroll pregnant women admitted to labor and delivery for the management of preterm labor and/or preterm premature rupture of membranes from 28-36 weeks gestation. Based on sonographic thymus measurements, the investigators will develop a clinical prediction tool to identify babies who are at increased risk for adverse neonatal outcomes. A reliable non-invasive predictor of adverse neonatal outcome using thymic ultrasound measurements has the potential to affect clinical management, improve outcomes for premature babies, and direct further research efforts.
Key facts
- Study ID
- NCT01975792
- Run by
- University of Pennsylvania
- People needed
- 125
- Starts
- 2013-03-01
- Expected to finish
- 2014-04-01
- Last updated by the study team
- 2017-03-30
Who can join
Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Singleton pregnancy between 28-36 weeks gestation
- Active spontaneous preterm labor symptoms (contractions, cervical dilatation and/or PPROM)
You may not qualify if…
- Non-singleton pregnancies
- Gestational hypertension/preeclampsia
- Major fetal anomalies
- Known fetal aneuploidy
- Intrauterine Fetal Demise
Where it is running
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.